Study of Treatment Response on IgG4 Related Disease (IgG4RD)
NCT02458196 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2017-01-24
Summary
This is an open-label randomized controlled trial to compare the efficacy of Prednisone alone and combination therapy of Prednisone and Mycophenolate mofetil in IgG4RD patients.
Conditions
Interventions
- DRUG
-
Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
- DRUG
-
Prednisone and Mycophenolate mofetil
Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months. Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months.
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Principal Investigators
-
Wen Zhang, Professor · Peking Union Medical College Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-30
- Primary Completion
- 2017-06-30
- Completion
- 2018-06-30
Countries
- China
Study Locations
More Related Trials
-
Leflunomide for Maintenance of Remission in IgG4 Related Disease
NCT02703194 ·Status: COMPLETED ·Phase: PHASE4
-
Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RD
NCT04539197 ·Status: UNKNOWN
-
Iguratimod as Treatment for Refractory Lupus Nephritis
NCT03054545 ·Status: UNKNOWN ·Phase: NA
-
The Iguratimod Effect on Lupus Nephritis (IGeLU)
NCT02936375 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
NCT04305197 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients
NCT04136106 ·Status: UNKNOWN
-
Study of Sirolimus in IgG4-related Disease
NCT05746689 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
NCT04077684 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RD06-04 in Patients With Active Autoimmune Diseases
NCT06548620 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
NCT06497361 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216 ·Status: TERMINATED ·Phase: PHASE2
-
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
NCT01946880 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT03951259 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose IL-2( Interleukin-2) Treatment in SLE
NCT02084238 ·Status: COMPLETED ·Phase: NA
-
Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis
NCT01042457 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial Treatment in Lupus Nephritis
NCT01299922 ·Status: WITHDRAWN ·Phase: PHASE3
-
Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
NCT01773616 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
NCT00423098 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-infection of Low-does IL-2 in SLE
NCT02932137 ·Status: COMPLETED ·Phase: NA
-
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
NCT02949349 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
NCT06015230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
NCT00001789 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus
NCT06852573 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2